A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

364

Participants

Timeline

Start Date

August 11, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

December 29, 2026

Conditions
HER2-expressing Advanced Solid Tumors
Interventions
DRUG

SHR-A1811 combined with Pyrotinib.

SHR-A1811 combined with Pyrotinib

DRUG

SHR-A1811 combined with other antitumor therapies

SHR-A1811 combined with other antitumor therapies

Trial Locations (15)

100142

RECRUITING

Peking University Cancer Hospital & Institute-Department of Gastrointestinal Oncology, Beijing

230001

RECRUITING

Anhui Provincial Hospital, Hefei

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital-Department of digestive oncology, Tianjin

330006

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

330200

RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

400016

RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

410031

RECRUITING

Hunan Cancer Hospital, Changsha

430079

RECRUITING

Hubei Cancer Hospital-Department of Abdominal Oncology, Wuhan

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University-Department of Medical Oncology, Zhengzhou

530021

RECRUITING

Guangxi Medical University Affiliated Tumor Hospital, Nanning

710061

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

050000

RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Unknown

RECRUITING

Harbin Medical University Cancer Hospital-The Eighth Department of Internal Medicine, Harbin

030013

RECRUITING

Shanxi Provincial Cancer Hospital-Gastroenterology Department, Taiyuan

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY